In the present study, in order to identify the gene expression profile of elderly (≥65-year-old) DLBCL patient’s responders and non-responders to the therapy with CHOP and R-CHOP, we benefited from a publicly available dataset (GSE10846) (7). This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.